US court upheld Astellas' Myrbetriq patent against Zydus

news18.com

Astellas Pharma secured a preliminary win against Zydus Lifesciences in a patent dispute, causing Zydus shares to drop significantly. The US District Court for Delaware upheld the validity of Astellas' patent for Myrbetriq, a medication for overactive bladder, against Zydus. The court ruled Zydus failed to prove its invalidity claims. Myrbetriq, containing mirabegron, is used to treat overactive bladder and neurogenic detrusor overactivity. Further litigation regarding infringement and damages is scheduled for 2026.


With a significance score of 2.7, this news ranks in the top 21% of today's 25338 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


US court upheld Astellas' Myrbetriq patent against Zydus | News Minimalist